Sign Up for Keystone Heart Updates
US
EU
Presentations
- Clinical Evidence
- Product Overview
- Case Presentations
- Symposia
- Healthcare Economics
- Neurological effects
- DW-MRI
- Clinical Data
TriGUARD 3™ Cerebral Embolic Protection Device Data Review
Jeffrey W. Moses, M.D.
Building the Evidence for CEP in TAVR: A Critical Review of the Clinical Trial Data
Jeffrey W. Moses, MD
ProtectionThe Search for Meaningful Measures of ClincialEfficacy: NeuroARCand Beyond
Alexandra Lansky, MD
What You Need to Know About Cerebral Embolic Protection (CEP): The Need for CEP
Dr. Martin B. Leon, MD
Update on Clinical Evidence to Support Cerebral Embolic Protection (CEP) During TAVR
Dr. Jeffrey W. Moses, MD
Meaningful End-Points of CEP Clinical Trials to Support Adoptions – Major Stroke, Minor Stroke, Imaging?
Dr. Rahul Sharma, MD
Diagnostic Considerations and NeuroARC
Dr. Alexandra Lansky, MD
TriGUARD 3™ Cerebral Embolic Protection Device Protection During TAVR
Tamim Nazif, M.D.
Practical Considerations and Design Requirements for Clinically Relevant CEP: The Keystone TriGUARD 3™ Cerebral Embolic Protection Device
Tamim Nazif, M.D.
TriGUARD 3™ Cerebral Embolic Protection Device Case
Michael Mack, M.D.
TCT 2017 Keystone Heart Symposium
TVT 2017 Keystone Heart Presentations
Economic Impact of Cerebral Embolic Protection: Important Considerations as TAVR Moves to Lower-Risk Patients
Dr. Hemal Gada, MD, MBA
A critical review of the neurological effects of invasive cardiac procedures
Pieter Stella, MD, PhD
The Evidence and Clinical Need Justifies the Widespread Use of Embolic Protection During TAVR
Samir Kapadia, MD
Brain Emboli: Clinical Consequences and Brain Injury
Dr. Kevin Abrams, MD
Mitigating Stroke Risk in TAVR: Important Considerations as TAVR Moves to Lower-Risk Patients
Dr. Benjamin Z. Galper, MD, MPH
Keystone Heart Reflect Neurology
Dr. Daryl Gress
Keystone Importance of DW MRI
John Forrest, M.D.
NeuroProtection with the TriGuard™ Cerebral Embolic Protection Device
Dr. Alexandra Lansky, MD
The Spectrum of Neurologic Events after TAVR: Insights from NueroARC
Dr. Alexandra Lansky, MD
TriGuard™ Cerebral Embolic Protection Device During TAVR: A Multicenter Real World Experience
Dr. Alexandra Lansky, MD
Cerebrovascular Complications after Valve Intervention: Incidence and New Standardized Definitions on behalf of NeuroARC
Dr. Alexandra Lansky, MD
The Only Cerebral Embolic Protection Device Designed to Cover all Three Major Arotic Vessels.
